Meeting
2017 ASCO Annual Meeting
ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.
Authors
Maeve Aine Lowery
Memorial Sloan Kettering Cancer Center and Weil Cornell Medical College, New York, NY
Maeve Aine Lowery , Ghassan K. Abou-Alfa , Juan W. Valle , Robin Kate Kelley , Lipika Goyal , Rachna T. Shroff , Milind M. Javle , Mitesh J. Borad , James M. Cleary , Anthony B. El-Khoueiry , Johanna C. Bendell , Teresa Macarulla , Arndt Vogel , Christopher Korth , Liewen Jiang , Camelia Gliser , Bin Wu , Samuel V. Agresta , Shuchi Sumant Pandya , Andrew X. Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02989857
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS4142)
DOI
10.1200/JCO.2017.35.15_suppl.TPS4142
Abstract #
TPS4142
Poster Bd #
128b
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
First Author: Ghassan K. Abou-Alfa
Poster
2020 ASCO Virtual Scientific Program
INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.
First Author: Ingo K. Mellinghoff
Poster
2020 Gastrointestinal Cancers Symposium
Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy study.
First Author: Bin Fan
Poster
2018 ASCO Annual Meeting
AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.
First Author: Eytan Stein